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Abstract 
We report herein the characterization f a mouse monoclonal antibody (Mab) raised against he recombinant NH2-terminal heparin-binding 
domain (rHBD) of human endothelial cell thrombospondin (TSP). The antibody, a IgG1 Q¢), hereafter referred to as V58A4, reacted with two rHBD, 
TSPN18 and TSPN28 (i.e. 18 kDa and 28 kDa, respectively) with an affinity constant of 1.33 x 10 -s M. However, V58A4 failed to recognize native 
or deglycosylated forms of TSP purified from platelets or endothelial cells, as well as a 25-30 kDa HBD fragment produced by limited proteolysis 
of native TSP. In contrast, Mab V58A4 was shown to react with larger HBD fragments (50--60 kDa) that were present in platelet or endothelial cell 
extracts and could be retained on a heparin-Sepharose column at low salt concentrations. These fragments also reacted with MA-II, a mouse Mab 
(IgGl), which recognizes both rHBD and HBD as well as intact TSP. Thus, V58A4 Mab appears to selectively recognize naturally occurring HBD 
fragments of TSP and may thus prove to be useful for detecting TSP proteolysis in situ under various physiopathological onditions. 
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1. Introduction 
Thrombospondin (TSP) is a 450 kDa platelet 0c-gran- 
ule glycoprotein that is synthesized and secreted by a 
large variety of cells in culture [1]. Newly synthesized 
TSP is incorporated into the extracellular matrix where 
it may interact with several molecules, including fi- 
bronectin, laminin, type V collagen, heparan sulfate pro- 
teoglycans and, as recently reported, TGF-fl (reviewed 
in [24]). TSP is a multifunctional molecule which mod- 
ulates cell adhesion, proliferation, migration and differ- 
entiation [1]. TSP exerts an anti-proliferative effect on 
bFGF-treated endothelial cells and was thus considered 
up until recently as an anti-angiogenic factor [5]. This 
finding, however, is controversial [6]. 
The interaction of TSP with heparin involves different 
sequences that are contained within the globular NH2- 
terminal heparin-binding domain (HBD) and the type I
repeats [7-9]. Both the HBD and synthetic peptides from 
the type I repeats containing the consensus equence 
Trp-Ser-Pro-Trp have been shown to modulate ndothe- 
lial cell proliferation, adhesion and motility [9-11]. In 
addition, the HBD has been shown to be essential for the 
binding of TSP to cell surface heparan-sulfate proteogly- 
cans, resulting in the endocytosis and degradation of 
TSP molecules [11,12]. 
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In an attempt to better characterize the structure- 
function relationship of the HBD, we raised monoclonal 
antibodies (Mabs) against two recombinant HBD (18 
and 28 kDa fragments). We describe in this paper the 
characterization of a Mab that failed to react with either 
native TSP or the 25-30 kDa HBD generated in vitro by 
different proteases but recognized 50q50 kDa HBD frag- 
ments occurring naturally in platelet and endothelial cell 
extracts. 
2. Materials and methods 
Recombinant heparin-binding fragments encompassing amino acid 
residues 1-242 (TSPN28) and 1-174 (TSPN18) of endothelial TSP were 
expressed in Escherichia coli strain A4255F- and purified as described 
in [10]. 
Female BALB/c mice, 6-8 weeks old, were immunized intradermally 
and in footpads with 50 gg of a mixture of TSPNI 8fl'SPN28 in com- 
plete Freund's adjuvant. Two booster injections were given intrader- 
matly at 3-week intervals with 100gg of the same antigen in incomplete 
Freund's adjuvant. Spleen cells of immunized mice were collected on 
day 47 and fused with non-secreting hypoxanthine (guanine)-phosphor- 
ibosyl transferase-deficient BALB/c X63-Ag-8 myeloma cells (Institut 
Pasteur, Paris) at a ratio of 5 : 1 in 40% polyethylene glycol (PEG-6000) 
using a standard protocol [13]. Fused cells were grown in DMEM 
supplemented with 2 mM glutamine, 100 IU penicillin, 50 gM hypoxan- 
thine, 10 gM azaserine and 10% fetal calf serum (FCS; Boehringer). 
Resulting clones were screened for anti-TSPN28 or anti-TSPN18 reac- 
tivity by ELISA as described below. The selected hybridoma cells were 
cloned three times by limiting dilution in the presence of mouse splenic 
feeder cells [14] and expanded as ascites in pristane-primed BALB/c 
female mice. 
Mabs V58A4 and MAII were purified by precipitation with 50% (v/v) 
saturated ammonium sulfate followed by chromatography on a Protein 
G-Fast Flow affinity column (Pharmacia Biotechnology). Mab V58A4 
was isotyped using the mouse-hybridoma subtyping ELISA kit 
(Boehringer) and radiolabelled with carrier-free Nat2SI (CIS Interna- 
0014-5793/94/$7.00 © 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(94)00460-D 
V. Morandi et al./FEBS Letters 346 (1994) 156-160 157 
tional, France) using the chloramine-T method to a specific activity of 
about 0.3--0.9 × 106 cprn//gg [15]. 
For binding assays, wells coated with TSPN18, TSPN28 or native 
TSP (10/.tg/ml) were blocked with 0.5% gelatin and incubated with 5 
gg/ml of purified Mabs (V58A4 or MAII) in PBS containing 0.05% 
Tween-20 and 2 mM CaC12 (PBS-Tween) for 1 h at 37°C. The reaction 
was developed by the sequential ddition of horseradish peroxidase- 
coupled Fab fragments o mouse immunoglobulins and ABTS sub- 
strate (Boehringer). The affinity of Mab V58A4 for its antigen was 
determined by incubating TSPN18- or TSPN28-coated wells with serial 
dilutions of the radiolabelled IgG. After washing, the radioactivity was 
counted and binding data were analysed by the Scatchard method [16]. 
Human platelet TSP was purified from the supernatants of thrombin- 
activated platelets as in [15]. Human endothelial cells from umbilical 
cord veins were cultured as in [17]. Endothelial TSP was purified from 
serum-free conditioned medium by chromatography on to gelatin- and 
heparin-Sepharose and concentrated by centrifugation i Centripep 
100 units (Amicon). Partially purified platelet or endothelial TSP was 
obtained by chromatographying thesupernatant of activated platelets 
or the serum-free conditioned medium of endothelial cells on a heparin- 
Sepharose column (Pharmacia) in10 mM Tris-HC1, pH 7.4, containing 
150 mM NaC1 and 1 mM CaCI2. The bound fraction was directly eluted 
with 0.55 M NaC1 in the same buffer. 
For the enzymatic digestion, platelet and endothelial cell TSP (90 
gg/100/tl) in Tris-HC1, pH 7.4, were incubated with either ~-thrombin 
(4 U/ml; Sigma), thermolysin (1: 100 w/w; Sigma), plasmin (4 U/ml; 
Sigma), trypsin (1:45 w/w; Sigma) or chymotrypsin (1:100 w/w; 
Worthington) at 37°C. Digestion was terminated by addition of 2 x 
electrophoresis ample buffer (1:2 v/v) [17]. 
For the N-deglycosylation experiments, proteins (40 gg/100 ~1) in 
0.02 M sodium phosphate, pH 7.0, were denatured for 3 min at 100*C 
in the presence of 0.1% SDS and 0.75% fl-mercaptoethanol, then incu- 
bated with 1 mM 1,10-phenanthrolin, 0.75% Nonidet P40 and 0.6 mU 
of N-glycanase (Genzyme) for 18-20 h at 37°C. For the O-deglycosyl- 
ation experiments, denatured proteins (40 gg/100 gl) in 0.02 M sodium 
phosphate buffer, pH 6.0, were incubated with 1 mM PMSF and 0.35 
U/ml neuraminidase for3 h at 37°C then with 1 mM 1,10-phenanthro- 
lin, 0.75% Nonidet P40 and 0.6 mU of O-glycanase (Genzyme) for 20 
h at 370C. Both deglycosylation reactions were stopped by adding 5 x 
electrophoresis sample buffer. As a control, purified fetuin (Sigma) was 
submitted to the same deglycosylation procedures and its mobility was 
compared with that of standard asialofetuin (Sigma). 
Samples of TSP or its fragments were electrophoresed under both 
reducing (5% fl-mercaptoethanol) or non-reducing conditions using the 
discontinuous Laemmli system [18]. The separated proteins were dec- 
trotransferred to Immobilon-P membranes (Millipore) and probed with 
5 gg/ml of V58A4 or MAII in PBS + Tween followed by incubation 
with horseradish peroxidase-conjugated anti-mouse IgG (1:2,000; 
Boehringer) and the chemioluminescent ECL reagent (Amersham). Ex- 
posure times to Hyperfilm-ECL (Amersbam) ranged between 10 and 
60 s. 
3. Results 
3.1. Characterization of Mab V58A4 
Screening of hybridomas by direct EL ISA against he 
recombinant fragments TSPN18 and TSPN28 resulted in 
the selection, among others, of a stable positive clone 
which we named V58A4. This hybr idoma was cloned 3 
times by l imiting dilution, and isotyping assays revealed 
that it secreted an IgG1 (to) antibody. In order to deter- 
mine its binding affinity (Ko), 125I-labeled V58A4 was 
titrated against adsorbed TSPN18 and TSPN28 frag- 
ments. Fig. 1 shows the curve obtained using TSPN18 
from which a dissociation constant of 1.33 x 10 -s M was 
calculated. Identical results were obtained when TSPN28 
was used as an antigen (not shown). 
3.2. Analysis of  the specificity of Mab V58A4 by ELISA 
The specificity of the interaction of Mab V58A4 with 
TSPN18 and TSPN28 was tested in an ELISA since the 
Mab did not recognize several other proteins, including 
fibronectin, f ibrinogen and laminin (Fig. 2). Surpris- 
ingly, despite its strong affinity for recombinant TSP 
fragments, the ant ibody failed to recognize adsorbed 
TSP, from either endothelial or platelet origin. Compa- 
rable results were obtained when incubat ion was per- 
formed in the presence of calcium or EDTA, and inde- 
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Fig. 1. Determination of V58A4 Mab affinity by radioimmunoassay. Radiolabeled Mab (~25I-V58A4) was added at various concentrations to 
microtiter wells coated with TSPNI8. After 1 h at 37"C, the wells were rinsed and the radioactivity counted for determination f bound Mab. (Inset) 
Scatchard analysis of the binding data: a dissociation constant of 1.33 x 10 -s M was determined. B = bound antibody; B/F = bound/free antibody. 
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Fig. 2. Analysis of the specificity ofV58A4 Mab by ELISA. Microtiter wells were coated overnight a 4°C with the various proteins and recombinant 
fragments (10/Jg/ml) as indicated. After blocking with 0.5% gelatin, wells were incubated with 5 pg/ml of V58A4 (dotted bars), or MA-II (hatched 
bars) or non-immune mouse IgG1 (black bars) in PBS/Tween buffer. The reaction was developed asdescribed in section 2and optical densities read 
at 405 nm. 
addition, preincubation of V58A4 with purified TSP be- 
fore its incubation with TSPN18-coated wells did not 
modify its reactivity, indicating that it also did not react 
with fluid-phase TSP. A positive control was provided 
by MA-II, a mouse Mab (IgG1) directed against the 
NH2-terminal domain of platelet TSP [19] that reacted 
with the recombinant fragments, TSPN18 and TSPN28, 
as well as with native platelet or endothelial cell TSP 
(Fig. 2). 
3.3. Analysis of the reactivity of Mab V58A4 with 
purified TSP by Western blot 
Mab V58A4 also failed to react with platelet or endo- 
thelial cell TSP in Western blot experiments conducted 
under both non-reducing or reducing conditions. It can 
be seen in Fig. 3 that V58A4 (lane 5) did not react with 
the reduced monomer (180 kDa) of platelet TSP which 
is well recognized by MA-II (lane 1). TSP samples ub- 
mitted to trypsin treatment resulted in the production of 
native HBD (major band at 30 kDa) which was recog- 
nized by MA-II (lanes 2, 3) but not by V58A4 (lanes 6, 
7). Also, V58A4 failed to react with 25-30 kDa HBD 
fragments generated by chymotrypsin, plasmin, ct- 
thrombin or thermolysin digestion (not shown). How- 
ever, MA-II and V58A4 reacted equally well with the 
recombinant fragment TSPN18 (lanes 4, 8). 
Deglycosylation protocols were then set up to look at 
the reactivity of V58A4 with deglycosylated native TSP, 
as well as with deglycosylated NH2-terminal fragments 
produced by thermolysin digestion. These combined 
procedures were expected to generate fragments more 
closely related to their recombinant counterparts, 
TSPNI 8 and TSPN28. In agreement with the fact that 
TSP contains approximately 5% of carbohydrates, de- 
glycosylation of either intact platelet TSP (Fig. 4A) or 
thermolysin-generated fragments (Fig. 4B) resulted in a 
slight increase in the mobility of the molecules which 
were still recognized by MA-II (lanes b and f compared 
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Fig. 3. Analysis of Mab reactivity against purified platelet TSP and its 
proteolytic fragments byWestern blot. Purified platelet TSP (5 pg/lane) 
either undigested (lanes 1, 5) or digested by trypsin (1:45, w/w) for 2 
min (lanes 2, 6) or 10 min (lanes 3, 7) at 37°C was analyzed by SDS- 
PAGE in a 17.5% slab gel under educing conditions. TSPN18 (5 pg) 
was loaded in lanes 4and 8. Blots were incubated with 5 pg/ml of either 
MA-II (lanes 1-4) or V58A4 (lanes 5-8). 
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Fig. 4. Analysis of Mab reactivity against deglycosylated forms of TSP 
by Western blot. (A) Intact (lanes a, c) or deglycosylated (lanes b, d) 
platelet TSP was analysed (5 gg/lane) under reducing conditions in a 
7.5% slab gel. (B) Intact (lanes e, g) or deglycosylated (lanes f, h) TSP 
was digested with thermolysin (1 : 100, w/w) for 60 rain at 37°C and 
analyzed (5/zg/ml) in reducing conditions on a 17.5% slab gel. Blots 
were incubated with 5 gg/ml of either MA-II (lanes a, b, e, f) or V58A4 
(lanes c, d, g, h). 
3.4. Analysis of the reactivity of Mab V58A4 with platelet 
and endothelial cell extracts 
Original data from Lawler and Slayter [20] indicated 
that the fragments generated from purified platelet TSP 
by a series of proteases are distinct from those that may 
be naturally produced during the platelet activation 
process and/or isolation procedure. In an attempt to de- 
tect additional heparin-binding peptides that would be 
generated under more physiological conditions, we have 
analyzed the supernatants from thrombin-activated 
platelets after only one fractionation on a heparin- 
Sepharose column. In these xperiments, we used 0.15 M 
NaC1 instead of 0.25 M NaC1 in the binding buffer in 
order to retain all the heparin-binding peptides whatever 
their affinity for heparin. Then, we performed a direct 
elution with 0.55 M NaC1 instead of the stepwise lution 
with increasing NaC1 concentrations. Finally, we omit- 
B 
ted the gel-filtration step in order not to eliminate low 
molecular weight heparin-binding fragments of TSP. 
Analysis of the heparin-bound fraction by Western 
blot under educing conditions (Fig. 5) indicated strong 
reactivity of Mab V58A4 with two bands of molecular 
weights of 51 and 60 kDa (lane b). These fragments were 
also recognized by MA-II (lane a), indicating that they 
comprised the NH2-terminus of TSP. The same frag- 
ments were also recognized under non-reducing condi- 
tions, but they were apparently present in lower amounts 
(lane e). Under these conditions, V58A4 also reacted 
with a high molecular weight band situated just beneath 
the band of intact TSP recognized by Mab MA-II (lane 
f). This band probably corresponds to a partially de- 
graded form of TSP which has retained 50-60 kDa NHE- 
terminus fragments till attached by disulfide bonds. 
Analysis of heparin-binding peptides prepared from the 
conditioned media of endothelial cells using the same 
protocol also indicated a strong reactivity of Mab MA-II 
(lane c) and Mab V58A4 (lane d) with a 60 kDa polypep- 
tide under educing conditions. 
4. Discussion 
Mabs directed against specific domains of multifunc- 
tional molecules uch as fibronectin, laminin and TSP 
have proved to be essential tools for characterizing the 
structure-function relationship of these glycoproteins [4]. 
In the present work, we have characterized a new 
Mab, V58A4, raised against a recombinant NH2-termi- 
nus HBD of human endothelial cell TSP. The main fea- 
ture of this Mab is that it recognizes TSP fragments of 
molecular weights of 50-60 kDa, whereas it fails to react 
with either native TSP or the 25-30 kDa HBD generated 
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Fig. 5. Analysis of heparin-binding peptides from platelet or endothelial cell preparations by Western blot. Heparin-binding lmptides (10/zg/lane) 
prepared from the supernatant ofthrombin-activated platelets (lanes a, b, e, f) or from the culture medium of endothelial cells (lanes c, d) were analyzed 
by SDS-PAGE on a 7.5% slab gel under reducing (A) or non-reducing conditions (B). Blots were incubated with 5/ag/ml of MA-II (lanes a, c, f) 
or V58A4 (lanes b, d, e). The arrow on top of the blot points to the material recognized by V58A4 situated just beneath the band of intact TSP. 
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were not detected in purified TSP preparations obtained 
from the supernatants of thrombin-activated platelets 
after stepwise lution of heparin-binding molecules from 
a heparin-Sepharose column followed by gel-exclusion 
chromatography [15]. However, the direct elution of a 
TSP-enriched fraction from the heparin-Sepharose col- 
umn with 0.55 M NaC1 allowed us to collect additional 
HBD fragments probably displaying a weaker affinity 
for heparin. Alternatively, these fragments may have 
been eliminated from the purified TSP preparations by 
the gel-exclusion chromatography. Our data suggest that 
the recognition of the HBD of TSP by V58A4 is modu- 
lated by structural conformational elements ince the 
immunoreactive forms of native HBD need to contain 
additional amino acid sequences, probably comprising 
the procollagen domain of TSP and part of its type I 
repeats [2]. In this respect, the epitope recognized by 
V58A4 appears to be different from that recognized by 
MA-II and may not be a linear sequence. This is sup- 
ported by the observation that the epitope for V58A4, 
but not that for MA-II, was lost when the recombinant 
HBD was treated by cyanogen bromide to generate three 
polypeptides (V. Morandi and C. Legrand, personal ob- 
servations). 
The identification of the epitope for V58A4 remains 
to be established. Additional work should also include 
the search for the occurrence of 50450 kDa fragments in 
vitro or in situ, either as secretion products of different 
cells in culture or as degradation fragments of native 
TSP. The generation of such fragments could take place 
during the degradation of the extracellular matrix which 
accompanies physiopathological events such as inflam- 
mation, tissue repair, angiogenesis or tumor invasion 
[21]. In this respect, an antibody such as V58A4 that 
would specifically recognize degraded forms of a matrix 
protein should prove to be useful to detect proteolysis n 
tissues or in biological fluids. 
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